Key facts
- This page summarizes Brendan Teehan's Form 4 filing for ACADIA PHARMACEUTICALS INC (ACAD).
- 4 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 27 Mar 2024, 20:00.
Brendan Teehan - 25 Mar 2024 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)
- Reporting relationship
- EVP, COO, HEAD OF COMMERCIAL
- Issuer ticker
- ACAD
- Reported as of
- 25 Mar 2024
- Net transaction value
- -$92,006
- SEC form
- 4
- Accepted by SEC
- 27 Mar 2024, 20:00:16 UTC
- Prior SEC filing
- 27 Feb 2024
- Next SEC filing
- 09 Apr 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jennifer J. Rhodes, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Brendan Teehan filed Form 4 for ACADIA PHARMACEUTICALS INC (ACAD) on 27 Mar 2024.
Change
- Previous filing in this sequence was filed on 27 Feb 2024.
- Current net transaction value: -$92,006.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ACAD
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +10,048
- Change %
- +32%
- Price
- $0.000000
- Shares after
- 41,480
- Date
- 25 Mar 2024
- Ownership
- Direct
- Footnotes
- F1
ACAD
transaction
Common Stock
Sale
- Transaction value
- $92,006
- Shares
- -5,140
- Change %
- -12%
- Price
- $17.90
- Shares after
- 36,340
- Date
- 27 Mar 2024
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ACAD
transaction
Derivative
Stock Options (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +89,516
- Change %
- Price
- $0.000000
- Shares after
- 89,516
- Date
- 25 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 89,516
- Exercise price
- $17.84
- Footnotes
- F3
ACAD
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +27,460
- Change %
- Price
- $0.000000
- Shares after
- 27,460
- Date
- 25 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 27,460
- Exercise price
- Footnotes
- F4, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on April 5, 2022 at 50% of target.
Footnote F2
The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of performance stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
Footnote F3
25% of the shares subject to the Stock Option will vest and become exercisable on March 25, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
Footnote F4
Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
Footnote F5
The restricted stock units vest in four equal annual installments beginning March 25, 2025.